We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$704M
AUM Growth
+$37.8M
Cap. Flow
+$141M
Cap. Flow %
19.98%
Top 10 Hldgs %
44.68%
Holding
54
New
11
Increased
21
Reduced
11
Closed
7
Avg Time Held
1 year
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
CNTX icon
Context Therapeutics
CNTX
+$25.4M
2
ZLAB icon
Zai Lab
ZLAB
+$22.2M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.8M
4
SRRK icon
Scholar Rock
SRRK
+$13.6M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$11.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$589M
$93.2M 13.23%
7,648,268
– –
2021 Q1
15 quarters
CRNX icon
2
DELISTED
Crinetics Pharmaceuticals
CRNX
$31.5M 4.48%
617,035
+91,190
+17% +$5.1M
2021 Q3
13 quarters
EWTX icon
3
Edgewise Therapeutics
EWTX
$4.51B
$28.8M 4.09%
1,079,316
+162,150
+18% +$5.16M
2024 Q1
3 quarters
INSM icon
4
Insmed
INSM
$31.7B
$26.9M 3.82%
389,611
-225,780
-37% -$16.3M
2022 Q4
8 quarters
NTRA icon
5
Natera
NTRA
$42B
$25.4M 3.61%
160,626
-16,473
-9% -$2.4M
2024 Q1
3 quarters
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$6.24B
$24.4M 3.46%
589,579
+96,856
+20% +$4.04M
2024 Q2
2 quarters
IRON icon
7
Disc Medicine
IRON
$3.47B
$22M 3.12%
346,401
+34,640
+11% +$2M
2023 Q4
4 quarters
LNTH icon
8
Lantheus
LNTH
$6.68B
$21.1M 3%
236,213
+86,031
+57% +$8.38M
2024 Q2
2 quarters
ZLAB icon
9
Zai Lab
ZLAB
$2.74B
$21M 2.97%
+800,000
New +$22.2M
2024 Q4
0 quarters
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$20.4M 2.9%
702,981
+14,006
+2% +$585K
2024 Q2
2 quarters
IOVA icon
11
Iovance Biotherapeutics
IOVA
$3.38B
$19.8M 2.81%
2,673,905
+267,191
+11% +$2.48M
2022 Q2
10 quarters
PTCT icon
12
PTC Therapeutics
PTCT
$4.87B
$19.6M 2.79%
434,767
+345,052
+385% +$14.8M
2024 Q3
1 quarter
WVE icon
13
Wave Life Sciences
WVE
$536M
$18.4M 2.62%
1,489,237
+864,766
+138% +$11.5M
2024 Q3
1 quarter
SRRK icon
14
Scholar Rock
SRRK
$6.15B
$18M 2.55%
+416,144
New +$13.6M
2024 Q4
0 quarters
MLTX icon
15
MoonLake Immunotherapeutics
MLTX
$939M
$17.1M 2.42%
315,230
-33,833
-10% -$1.73M
2023 Q2
6 quarters
OLMA icon
16
Olema Oncology
OLMA
$626M
$17M 2.41%
2,912,550
+231,954
+9% +$2.32M
2023 Q2
6 quarters
RARE icon
17
Ultragenyx Pharmaceutical
RARE
$1.76B
$16.5M 2.34%
391,018
+61,285
+19% +$3.04M
2024 Q1
3 quarters
CNTX icon
18
Context Therapeutics
CNTX
$15.5M
$15.4M 2.19%
+14,705,882
New +$25.4M
2024 Q4
0 quarters
GH icon
19
Guardant Health
GH
$19.7B
$13.8M 1.96%
452,739
-46,431
-9% -$1.31M
2024 Q2
2 quarters
RVMD icon
20
Revolution Medicines
RVMD
$34.5B
$13.7M 1.95%
313,817
+22,426
+8% +$1.13M
2021 Q3
13 quarters
ITOS icon
21
DELISTED
iTeos Therapeutics
ITOS
$13.4M 1.9%
1,745,943
– –
2020 Q3
17 quarters
RNAC icon
22
Cartesian Therapeutics
RNAC
$180M
$12.9M 1.83%
721,139
+91,716
+15% +$1.86M
2024 Q2
2 quarters
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$236M
$12.8M 1.82%
1,020,559
-45,814
-4% -$690K
2024 Q3
1 quarter
AKRO icon
24
DELISTED
Akero Therapeutics
AKRO
$12.8M 1.82%
460,617
+68,073
+17% +$2.06M
2024 Q1
3 quarters
TRVI icon
25
Trevi Therapeutics
TRVI
$1.96B
$12.8M 1.81%
3,094,896
+1,556,379
+101% +$4.98M
2024 Q1
3 quarters

Similar funds

MPM BioImpact's Q4 2024 Portfolio in Review

As of Q4 2024, MPM BioImpact held 54 positions worth $704M, up 5.7% from $667M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

MPM BioImpact deployed $141M of net new capital in Q4 2024, opening 11 new positions and adding to 21 existing holdings. Its largest new stake was Context Therapeutics: 14,705,882 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $16.3M trimmed.

  • MPM BioImpact's largest Q4 2024 buy was Context Therapeutics: 14,705,882 shares worth $15.4M.
  • MPM BioImpact added most to PTC Therapeutics in Q4 2024, an estimated $14.8M increase.
  • MPM BioImpact's biggest Q4 2024 reduction was Insmed, cutting an estimated $16.3M.
  • MPM BioImpact fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $15.4M.
  • MPM BioImpact's ten largest holdings make up 45% of its $704M portfolio in Q4 2024.
  • MPM BioImpact opened 11 new positions and closed 7 in Q4 2024.
  • MPM BioImpact's portfolio value rose 5.7% quarter-over-quarter to $704M.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.